Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ronrydellon Dec 02, 2014 5:27pm

293 Views

Post# 23187712

RE:RE:Drip, Drip, Drip etc

His analysis will always be the same ...we'll all lose our money and/or Ken Dart will buy the shell as an alternative to IPO and put a profitable company in it. We may all get an opportunity to tender our shares for a buck and most small shareholders will be happy to get rid of this nightmare. Those are his thoughts. 😢

Bullboard Posts

Soma Gold poised to extend profitable track record